Cargando…
Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019()
BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 200...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368817/ https://www.ncbi.nlm.nih.gov/pubmed/37502094 http://dx.doi.org/10.1016/j.ijcrp.2023.200196 |
_version_ | 1785077585386930176 |
---|---|
author | Thyagaturu, Harshith Alyami, Bandar Roma, Nicholas Gonuguntla, Karthik Bondi, Gayatri Patel, Brijesh |
author_facet | Thyagaturu, Harshith Alyami, Bandar Roma, Nicholas Gonuguntla, Karthik Bondi, Gayatri Patel, Brijesh |
author_sort | Thyagaturu, Harshith |
collection | PubMed |
description | BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 2002 to 2019 to identify adult (age >18 years) cancer patients with HTN using appropriate International Classification of Disease (ICD)-9 and ICD-10 codes. Benign and uncertain neoplasms were excluded. P-trend values were calculated using weighted logistic regression with “year” as the predictor variable. RESULTS: We identified ∼46 million adult hypertensive cancer patients with an increasing trend from 2002 to 2019 (3.3 m–6.7 m). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in hypertensive cancer patients increased steadily, while diuretics and combined drugs decreased. Calcium channel blocker (CCB) use increased since 2014–15. In cancer patients with heart failure (HF), beta-blocker (BB) use increased; however, diuretic use peaked in 2014–15 and declined. The use of ACEi/ARB in cancer patients with Diabetes (DM) has increased, whereas BB, CCB, and diuretic use remained stable. Hypertensive cancer patients with Atherosclerotic Cardiovascular Disease (ASCVD) had increased ACEI/ARB use. Combination AHT use has decreased broadly. CONCLUSION: The ACEI/ARB and CCB use trends increased over the past two decades, whereas diuretics have declined. In cancer patients with DM or ASCVD, the use of ACEI/ARB is trending up. BB use showed an increasing trend in patients with HF. Combined AHT and diuretics use decreased. Total expenditure and out-of-pocket expenditure have a decreasing trend for all AHT medications. |
format | Online Article Text |
id | pubmed-10368817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103688172023-07-27 Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() Thyagaturu, Harshith Alyami, Bandar Roma, Nicholas Gonuguntla, Karthik Bondi, Gayatri Patel, Brijesh Int J Cardiol Cardiovasc Risk Prev Research Paper BACKGROUND: Hypertension (HTN) is the most frequently reported comorbidity in patients with malignancy. This study was conducted to assess the trend of different antihypertensive (AHT) medications used in cancer patients. METHODS: We used the Medical Expenditure Panel Survey (MEPS) database from 2002 to 2019 to identify adult (age >18 years) cancer patients with HTN using appropriate International Classification of Disease (ICD)-9 and ICD-10 codes. Benign and uncertain neoplasms were excluded. P-trend values were calculated using weighted logistic regression with “year” as the predictor variable. RESULTS: We identified ∼46 million adult hypertensive cancer patients with an increasing trend from 2002 to 2019 (3.3 m–6.7 m). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) use in hypertensive cancer patients increased steadily, while diuretics and combined drugs decreased. Calcium channel blocker (CCB) use increased since 2014–15. In cancer patients with heart failure (HF), beta-blocker (BB) use increased; however, diuretic use peaked in 2014–15 and declined. The use of ACEi/ARB in cancer patients with Diabetes (DM) has increased, whereas BB, CCB, and diuretic use remained stable. Hypertensive cancer patients with Atherosclerotic Cardiovascular Disease (ASCVD) had increased ACEI/ARB use. Combination AHT use has decreased broadly. CONCLUSION: The ACEI/ARB and CCB use trends increased over the past two decades, whereas diuretics have declined. In cancer patients with DM or ASCVD, the use of ACEI/ARB is trending up. BB use showed an increasing trend in patients with HF. Combined AHT and diuretics use decreased. Total expenditure and out-of-pocket expenditure have a decreasing trend for all AHT medications. Elsevier 2023-07-10 /pmc/articles/PMC10368817/ /pubmed/37502094 http://dx.doi.org/10.1016/j.ijcrp.2023.200196 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Thyagaturu, Harshith Alyami, Bandar Roma, Nicholas Gonuguntla, Karthik Bondi, Gayatri Patel, Brijesh Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title | Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title_full | Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title_fullStr | Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title_full_unstemmed | Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title_short | Trends of antihypertensive use among patients with cancer and hypertension in the United States 2002–2019() |
title_sort | trends of antihypertensive use among patients with cancer and hypertension in the united states 2002–2019() |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368817/ https://www.ncbi.nlm.nih.gov/pubmed/37502094 http://dx.doi.org/10.1016/j.ijcrp.2023.200196 |
work_keys_str_mv | AT thyagaturuharshith trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 AT alyamibandar trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 AT romanicholas trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 AT gonuguntlakarthik trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 AT bondigayatri trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 AT patelbrijesh trendsofantihypertensiveuseamongpatientswithcancerandhypertensionintheunitedstates20022019 |